 Andrew Subudhi
Concepts (256)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebrovascular Circulation | 23 | 2017 | 219 | 4.570 |
Why?
| | Altitude | 28 | 2019 | 435 | 3.350 |
Why?
| | Hypoxia | 26 | 2017 | 956 | 3.350 |
Why?
| | Altitude Sickness | 20 | 2018 | 170 | 3.300 |
Why?
| | Acclimatization | 19 | 2018 | 147 | 2.830 |
Why?
| | Oxygen Consumption | 17 | 2019 | 587 | 2.130 |
Why?
| | Oxygen | 19 | 2019 | 851 | 2.000 |
Why?
| | Exercise | 20 | 2019 | 1642 | 1.750 |
Why?
| | Homeostasis | 7 | 2017 | 570 | 1.650 |
Why?
| | Middle Cerebral Artery | 7 | 2015 | 36 | 1.620 |
Why?
| | Blood Flow Velocity | 13 | 2017 | 388 | 1.220 |
Why?
| | Brain | 8 | 2016 | 2355 | 0.880 |
Why?
| | Carbon Dioxide | 10 | 2015 | 218 | 0.790 |
Why?
| | Arterial Pressure | 3 | 2016 | 99 | 0.710 |
Why?
| | Muscle Fatigue | 6 | 2014 | 94 | 0.670 |
Why?
| | Antioxidants | 6 | 2013 | 529 | 0.660 |
Why?
| | Quadriceps Muscle | 3 | 2013 | 104 | 0.630 |
Why?
| | Posture | 2 | 2017 | 152 | 0.580 |
Why?
| | Bicycling | 10 | 2011 | 86 | 0.550 |
Why?
| | Young Adult | 24 | 2019 | 10444 | 0.530 |
Why?
| | Muscle Contraction | 2 | 2007 | 388 | 0.460 |
Why?
| | Adult | 41 | 2019 | 30375 | 0.460 |
Why?
| | Exercise Test | 7 | 2019 | 547 | 0.460 |
Why?
| | Acute Disease | 8 | 2016 | 907 | 0.450 |
Why?
| | Regional Blood Flow | 4 | 2013 | 421 | 0.440 |
Why?
| | Physical Endurance | 6 | 2008 | 232 | 0.430 |
Why?
| | Radial Artery | 2 | 2013 | 66 | 0.420 |
Why?
| | Ultrasonography, Doppler, Transcranial | 7 | 2013 | 42 | 0.420 |
Why?
| | Spectroscopy, Near-Infrared | 6 | 2018 | 47 | 0.410 |
Why?
| | Oxidative Stress | 6 | 2018 | 1068 | 0.410 |
Why?
| | Athletic Performance | 2 | 2012 | 54 | 0.400 |
Why?
| | Acetazolamide | 2 | 2011 | 30 | 0.390 |
Why?
| | Hypoxia, Brain | 2 | 2011 | 10 | 0.390 |
Why?
| | Erythrocytes | 4 | 2017 | 568 | 0.390 |
Why?
| | Male | 42 | 2019 | 55396 | 0.380 |
Why?
| | Blood Pressure | 4 | 2017 | 1531 | 0.370 |
Why?
| | Cross-Over Studies | 7 | 2019 | 439 | 0.360 |
Why?
| | Hyperoxia | 2 | 2010 | 99 | 0.350 |
Why?
| | Hemoglobins | 4 | 2014 | 308 | 0.350 |
Why?
| | Atmospheric Pressure | 1 | 2010 | 18 | 0.340 |
Why?
| | Dexamethasone | 2 | 2011 | 316 | 0.340 |
Why?
| | Humans | 58 | 2019 | 114045 | 0.330 |
Why?
| | Pulmonary Gas Exchange | 4 | 2019 | 117 | 0.310 |
Why?
| | Motor Cortex | 1 | 2009 | 46 | 0.310 |
Why?
| | Pulmonary Ventilation | 4 | 2013 | 72 | 0.310 |
Why?
| | Competitive Behavior | 1 | 2008 | 38 | 0.290 |
Why?
| | Respiratory Mechanics | 1 | 2007 | 56 | 0.290 |
Why?
| | Physical Exertion | 2 | 2007 | 209 | 0.280 |
Why?
| | Frontal Lobe | 1 | 2007 | 141 | 0.270 |
Why?
| | Maximal Voluntary Ventilation | 1 | 2006 | 8 | 0.270 |
Why?
| | Receptor, Adenosine A2B | 2 | 2017 | 32 | 0.270 |
Why?
| | Prefrontal Cortex | 1 | 2009 | 263 | 0.260 |
Why?
| | Female | 25 | 2019 | 59324 | 0.250 |
Why?
| | Respiration | 5 | 2012 | 180 | 0.240 |
Why?
| | Double-Blind Method | 8 | 2011 | 1656 | 0.230 |
Why?
| | Adaptation, Physiological | 3 | 2016 | 484 | 0.230 |
Why?
| | Models, Cardiovascular | 3 | 2011 | 179 | 0.230 |
Why?
| | Cerebral Cortex | 1 | 2007 | 380 | 0.220 |
Why?
| | Sports | 3 | 2012 | 187 | 0.220 |
Why?
| | Single-Blind Method | 5 | 2012 | 259 | 0.200 |
Why?
| | Blood Gas Analysis | 5 | 2015 | 70 | 0.200 |
Why?
| | Carotid Artery, Internal | 2 | 2012 | 36 | 0.200 |
Why?
| | Vertebral Artery | 2 | 2012 | 27 | 0.200 |
Why?
| | Anaerobic Threshold | 3 | 2009 | 22 | 0.200 |
Why?
| | Rest | 4 | 2015 | 103 | 0.190 |
Why?
| | Heart Rate | 5 | 2014 | 710 | 0.190 |
Why?
| | Time Factors | 9 | 2016 | 6077 | 0.180 |
Why?
| | Muscle, Skeletal | 5 | 2018 | 1468 | 0.180 |
Why?
| | Skiing | 1 | 2001 | 42 | 0.180 |
Why?
| | Proteomics | 2 | 2018 | 815 | 0.170 |
Why?
| | Energy Metabolism | 3 | 2018 | 727 | 0.160 |
Why?
| | Adenosine | 2 | 2017 | 203 | 0.150 |
Why?
| | Metabolome | 2 | 2018 | 274 | 0.150 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2017 | 13 | 0.140 |
Why?
| | Inhalation | 2 | 2007 | 26 | 0.130 |
Why?
| | Sphingosine | 1 | 2016 | 33 | 0.130 |
Why?
| | Lysophospholipids | 1 | 2016 | 65 | 0.130 |
Why?
| | Syncope | 1 | 2016 | 38 | 0.130 |
Why?
| | Severity of Illness Index | 3 | 2013 | 2537 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2016 | 170 | 0.120 |
Why?
| | Carotid Arteries | 1 | 2016 | 180 | 0.120 |
Why?
| | Erythropoiesis | 1 | 2014 | 33 | 0.120 |
Why?
| | Glutathione | 3 | 2016 | 293 | 0.120 |
Why?
| | Tibet | 1 | 2014 | 28 | 0.120 |
Why?
| | Bolivia | 1 | 2014 | 62 | 0.110 |
Why?
| | Peru | 1 | 2014 | 54 | 0.110 |
Why?
| | Foramen Ovale, Patent | 1 | 2015 | 45 | 0.110 |
Why?
| | Surveys and Questionnaires | 5 | 2013 | 4595 | 0.110 |
Why?
| | Mountaineering | 2 | 2011 | 45 | 0.110 |
Why?
| | Lipid Peroxidation | 2 | 2004 | 139 | 0.100 |
Why?
| | Carotid Artery, External | 1 | 2012 | 3 | 0.100 |
Why?
| | Healthy Volunteers | 3 | 2018 | 191 | 0.100 |
Why?
| | Analysis of Variance | 4 | 2010 | 1218 | 0.100 |
Why?
| | Motor Activity | 2 | 2014 | 635 | 0.100 |
Why?
| | Pulse Wave Analysis | 1 | 2012 | 207 | 0.100 |
Why?
| | Body Temperature Regulation | 1 | 2012 | 72 | 0.100 |
Why?
| | Malondialdehyde | 2 | 2009 | 28 | 0.100 |
Why?
| | Blood Proteins | 1 | 2013 | 222 | 0.100 |
Why?
| | Skull | 1 | 2012 | 119 | 0.100 |
Why?
| | Glycolysis | 3 | 2018 | 224 | 0.100 |
Why?
| | Cold Temperature | 1 | 2012 | 125 | 0.090 |
Why?
| | Vasoconstriction | 1 | 2012 | 177 | 0.090 |
Why?
| | Pulmonary Edema | 2 | 2010 | 109 | 0.090 |
Why?
| | Cell Membrane Permeability | 1 | 2011 | 83 | 0.090 |
Why?
| | Lactic Acid | 3 | 2009 | 272 | 0.090 |
Why?
| | Forecasting | 1 | 2012 | 331 | 0.090 |
Why?
| | Cerebral Arteries | 1 | 2011 | 55 | 0.090 |
Why?
| | Hot Temperature | 1 | 2012 | 301 | 0.090 |
Why?
| | Oxidation-Reduction | 3 | 2018 | 917 | 0.090 |
Why?
| | Residence Characteristics | 1 | 2012 | 274 | 0.090 |
Why?
| | Running | 1 | 2012 | 207 | 0.090 |
Why?
| | Vasodilation | 1 | 2012 | 418 | 0.080 |
Why?
| | Fourier Analysis | 1 | 2009 | 39 | 0.080 |
Why?
| | Ribose | 1 | 2009 | 18 | 0.080 |
Why?
| | Reaction Time | 1 | 2011 | 373 | 0.080 |
Why?
| | Manometry | 1 | 2009 | 89 | 0.080 |
Why?
| | Algorithms | 3 | 2014 | 1469 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2011 | 178 | 0.080 |
Why?
| | Phosphorylation | 3 | 2018 | 1558 | 0.080 |
Why?
| | Exhalation | 1 | 2007 | 34 | 0.070 |
Why?
| | Oxyhemoglobins | 1 | 2007 | 20 | 0.070 |
Why?
| | Pentose Phosphate Pathway | 2 | 2018 | 47 | 0.070 |
Why?
| | Nutritional Requirements | 1 | 2007 | 75 | 0.070 |
Why?
| | Blood Volume | 1 | 2007 | 57 | 0.070 |
Why?
| | Cognition | 1 | 2014 | 990 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2009 | 1791 | 0.070 |
Why?
| | GPI-Linked Proteins | 2 | 2017 | 54 | 0.070 |
Why?
| | 5'-Nucleotidase | 2 | 2017 | 35 | 0.070 |
Why?
| | 2,3-Diphosphoglycerate | 2 | 2016 | 28 | 0.070 |
Why?
| | Sports Medicine | 1 | 2008 | 103 | 0.070 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2013 | 465 | 0.060 |
Why?
| | Feeding and Eating Disorders | 1 | 2007 | 103 | 0.060 |
Why?
| | Drinking | 1 | 2005 | 33 | 0.060 |
Why?
| | Recovery of Function | 1 | 2009 | 573 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2007 | 2764 | 0.060 |
Why?
| | Lung | 2 | 2015 | 3521 | 0.060 |
Why?
| | Physical Education and Training | 1 | 2004 | 62 | 0.060 |
Why?
| | Exercise Tolerance | 1 | 2006 | 212 | 0.060 |
Why?
| | Placebos | 1 | 2004 | 197 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2006 | 362 | 0.050 |
Why?
| | Partial Pressure | 2 | 2013 | 30 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2017 | 4680 | 0.050 |
Why?
| | Adolescent | 3 | 2017 | 17800 | 0.050 |
Why?
| | Hypercapnia | 2 | 2013 | 50 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2014 | 1726 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2004 | 522 | 0.050 |
Why?
| | DNA Damage | 1 | 2004 | 351 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2006 | 673 | 0.050 |
Why?
| | Chronic Disease | 1 | 2007 | 1577 | 0.050 |
Why?
| | Colorimetry | 1 | 2001 | 14 | 0.050 |
Why?
| | Carbonic Anhydrase Inhibitors | 2 | 2011 | 17 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1128 | 0.050 |
Why?
| | Inflammation | 1 | 2011 | 2464 | 0.050 |
Why?
| | Bone Density | 1 | 2004 | 432 | 0.040 |
Why?
| | Tidal Volume | 2 | 2012 | 75 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2017 | 2562 | 0.040 |
Why?
| | Brain Edema | 2 | 2011 | 59 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2011 | 9049 | 0.040 |
Why?
| | Dehydration | 2 | 2012 | 40 | 0.040 |
Why?
| | Purine Nucleotides | 1 | 2018 | 12 | 0.040 |
Why?
| | Carnitine | 1 | 2018 | 62 | 0.040 |
Why?
| | Proteolysis | 1 | 2018 | 142 | 0.040 |
Why?
| | Diet | 1 | 2004 | 1080 | 0.040 |
Why?
| | Random Allocation | 1 | 2018 | 328 | 0.040 |
Why?
| | Animals | 5 | 2017 | 31565 | 0.030 |
Why?
| | Mitochondria, Muscle | 1 | 2018 | 92 | 0.030 |
Why?
| | Ubiquitination | 1 | 2017 | 86 | 0.030 |
Why?
| | Bisphosphoglycerate Mutase | 1 | 2016 | 7 | 0.030 |
Why?
| | Glyceraldehyde-3-Phosphate Dehydrogenase (Phosphorylating) | 1 | 2016 | 6 | 0.030 |
Why?
| | Muscles | 1 | 2018 | 320 | 0.030 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 1 | 2016 | 41 | 0.030 |
Why?
| | Biomarkers | 3 | 2013 | 3397 | 0.030 |
Why?
| | Sulfur | 1 | 2016 | 46 | 0.030 |
Why?
| | Muscle Proteins | 1 | 2018 | 210 | 0.030 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 130 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2016 | 271 | 0.030 |
Why?
| | Purines | 1 | 2016 | 158 | 0.030 |
Why?
| | Intracranial Pressure | 1 | 2015 | 48 | 0.030 |
Why?
| | Arginine | 1 | 2016 | 236 | 0.030 |
Why?
| | Fatty Acids | 1 | 2018 | 380 | 0.030 |
Why?
| | Proteins | 1 | 2001 | 906 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2018 | 379 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2016 | 771 | 0.030 |
Why?
| | Amino Acids | 1 | 2018 | 445 | 0.030 |
Why?
| | Heart Auscultation | 1 | 2014 | 1 | 0.030 |
Why?
| | Heart Sounds | 1 | 2014 | 1 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2016 | 399 | 0.030 |
Why?
| | Acid-Base Equilibrium | 1 | 2013 | 29 | 0.030 |
Why?
| | Risk Factors | 3 | 2012 | 8614 | 0.030 |
Why?
| | Markov Chains | 1 | 2014 | 114 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 2013 | 55 | 0.030 |
Why?
| | Enzymes | 1 | 2013 | 62 | 0.030 |
Why?
| | Acute Lung Injury | 1 | 2016 | 268 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2014 | 131 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2013 | 3003 | 0.030 |
Why?
| | Cold Climate | 1 | 2012 | 8 | 0.030 |
Why?
| | Validation Studies as Topic | 1 | 2012 | 23 | 0.030 |
Why?
| | Frostbite | 1 | 2012 | 6 | 0.030 |
Why?
| | Hypocapnia | 1 | 2012 | 6 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2013 | 507 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2014 | 318 | 0.020 |
Why?
| | Heat Stress Disorders | 1 | 2012 | 40 | 0.020 |
Why?
| | Hypothermia | 1 | 2012 | 37 | 0.020 |
Why?
| | Health Facilities | 1 | 2012 | 71 | 0.020 |
Why?
| | Respiration Disorders | 1 | 2012 | 68 | 0.020 |
Why?
| | Body Composition | 2 | 2006 | 590 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2013 | 410 | 0.020 |
Why?
| | Blood Circulation Time | 1 | 2010 | 3 | 0.020 |
Why?
| | Constriction | 1 | 2010 | 45 | 0.020 |
Why?
| | Mice | 2 | 2017 | 14843 | 0.020 |
Why?
| | Vasomotor System | 1 | 2010 | 39 | 0.020 |
Why?
| | Blood-Brain Barrier | 1 | 2011 | 106 | 0.020 |
Why?
| | Headache | 1 | 2011 | 132 | 0.020 |
Why?
| | Software | 1 | 2014 | 526 | 0.020 |
Why?
| | Electrocardiography | 1 | 2012 | 561 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1690 | 0.020 |
Why?
| | Pulse | 1 | 2009 | 26 | 0.020 |
Why?
| | Free Radicals | 1 | 2009 | 99 | 0.020 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2010 | 127 | 0.020 |
Why?
| | Ventilators, Mechanical | 1 | 2009 | 52 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2009 | 138 | 0.020 |
Why?
| | Cardiac Output | 1 | 2008 | 143 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2011 | 445 | 0.020 |
Why?
| | Norepinephrine | 1 | 2008 | 201 | 0.020 |
Why?
| | Self Disclosure | 1 | 2007 | 59 | 0.020 |
Why?
| | Sleep | 1 | 2012 | 631 | 0.020 |
Why?
| | Dogs | 1 | 2008 | 331 | 0.020 |
Why?
| | Magnetics | 1 | 2007 | 39 | 0.020 |
Why?
| | Epinephrine | 1 | 2008 | 163 | 0.020 |
Why?
| | Lactates | 1 | 2007 | 78 | 0.020 |
Why?
| | Catecholamines | 1 | 2006 | 94 | 0.020 |
Why?
| | Urinalysis | 1 | 2005 | 64 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2009 | 459 | 0.020 |
Why?
| | Oximetry | 1 | 2005 | 79 | 0.020 |
Why?
| | Models, Biological | 1 | 2012 | 1611 | 0.020 |
Why?
| | Electromyography | 1 | 2007 | 326 | 0.020 |
Why?
| | Lipid Peroxides | 1 | 2004 | 9 | 0.010 |
Why?
| | Maximal Expiratory Flow Rate | 1 | 2004 | 3 | 0.010 |
Why?
| | Pilot Projects | 1 | 2009 | 1360 | 0.010 |
Why?
| | Signal Transduction | 1 | 2017 | 4501 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 183 | 0.010 |
Why?
| | Task Performance and Analysis | 1 | 2004 | 160 | 0.010 |
Why?
| | Equipment Design | 1 | 2005 | 503 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 725 | 0.010 |
Why?
| | Energy Intake | 1 | 2006 | 427 | 0.010 |
Why?
| | Linear Models | 1 | 2005 | 768 | 0.010 |
Why?
| | Clinical Protocols | 1 | 2004 | 232 | 0.010 |
Why?
| | Body Weight | 1 | 2005 | 868 | 0.010 |
Why?
| | Prevalence | 1 | 2007 | 2247 | 0.010 |
Why?
| | Data Collection | 1 | 2004 | 618 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2007 | 1168 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2008 | 3498 | 0.010 |
Why?
| | Child | 1 | 2014 | 18401 | 0.010 |
Why?
| | Prospective Studies | 1 | 2006 | 6195 | 0.010 |
Why?
| | Middle Aged | 1 | 2012 | 26605 | 0.010 |
Why?
| | United States | 1 | 2004 | 12137 | 0.000 |
Why?
|
|
Subudhi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|